Telix Quarterly Results and Investor Call / Webcast Notification
Telix today advises it will release its Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ended 31 March 2023 on Monday 17 April 2023 at market...
Read moreLatest News
Category: ASX
Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive
Telix today announces its financial results for the financial year ended 31 December...
Read more
Telix 2022 Full Year Results and Investor Call / Webcast Notification
Telix today advises it will release its Full Year Results and Annual Report for the period ended 31 December 2022 on Monday 27 February 2023 at market...
Read more
Notification of Investor Briefing: ASCO-GU ZIRCON Phase III Results Presentation
Telix advises that Associate Professor Brian Shuch, MD, Director, Kidney Cancer Program, UCLA Institute of Urologic Oncology (Los Angeles, California) and a Principal Investigator in the Phase III ZIRCON study...
Read more
Activities Report and Appendix 4C for December quarter
Telix today issues its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 31 December 2022 (Q4 2022). All figures are in AUD$ unless otherwise...
Read more
Presentation to J.P. Morgan Healthcare Conference and Q4 2022 Illuccix Revenue Update
Telix today advises it is presenting at the 41st Annual J.P. Morgan Healthcare Conference (9–12 January) in San Francisco. As part of the Company’s presentation (lodged with this announcement), Telix has...
Read more
ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances
Telix today announces that the completed pivotal Phase III ZIRCON study (ClinicalTrials.gov Identifier: NCT03849118) of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) has been selected for oral presentation...
Read more
Telix Announces Executive Leadership Appointments
Telix today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession...
Read more
First Patient Dosed in Phase II ‘IPAX-Linz’ Study of TLX101 for Glioblastoma Therapy
Telix today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with recurrent...
Read more
Telix Acquires Optimal Tracers
Telix today announces that it has entered into an agreement with Sacramento-based Northern California PET Imaging Center (NCPIC) to acquire Optimal Tracers, a radiochemistry development business providing radiochemistry process development...
Read more